JP6112449B2 - Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法 - Google Patents

Info

Publication number

JP6112449B2

JP6112449B2 JP2012520810A JP2012520810A JP6112449B2 JP 6112449 B2 JP6112449 B2 JP 6112449B2 JP 2012520810 A JP2012520810 A JP 2012520810A JP 2012520810 A JP2012520810 A JP 2012520810A JP 6112449 B2 JP6112449 B2 JP 6112449B2

Authority

JP

Japan

Prior art keywords

polyamine

mgbg

group

dose

alkyl

Prior art date

2009-07-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 title claims description 144
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 147
• 201000010099 disease Diseases 0.000 title description 102
• 238000000034 method Methods 0.000 title description 96
• 239000003814 drug Substances 0.000 title description 83
• 229960003539 mitoguazone Drugs 0.000 claims description 137
• 230000000694 effects Effects 0.000 claims description 65
• 239000008203 oral pharmaceutical composition Substances 0.000 claims description 19
• 230000000670 limiting effect Effects 0.000 claims description 5
• 239000008008 oral excipient Substances 0.000 claims description 3
• 229920000768 polyamine Polymers 0.000 description 204
• 150000001875 compounds Chemical class 0.000 description 150
• -1 MDL73811 Chemical compound 0.000 description 96
• 239000008194 pharmaceutical composition Substances 0.000 description 85
• 241000725303 Human immunodeficiency virus Species 0.000 description 79
• 239000000203 mixture Substances 0.000 description 77
• 125000000217 alkyl group Chemical group 0.000 description 76
• 238000011282 treatment Methods 0.000 description 73
• 239000003112 inhibitor Substances 0.000 description 72
• 230000015572 biosynthetic process Effects 0.000 description 70
• 230000036470 plasma concentration Effects 0.000 description 69
• 150000003839 salts Chemical class 0.000 description 55
• 229940079593 drug Drugs 0.000 description 54
• 241001465754 Metazoa Species 0.000 description 53
• 208000002193 Pain Diseases 0.000 description 53
• 102000004264 Osteopontin Human genes 0.000 description 51
• 108010081689 Osteopontin Proteins 0.000 description 51
• 230000036407 pain Effects 0.000 description 51
• 125000003118 aryl group Chemical group 0.000 description 46
• 229910052739 hydrogen Inorganic materials 0.000 description 45
• 208000035475 disorder Diseases 0.000 description 44
• 210000002381 plasma Anatomy 0.000 description 42
• 238000001990 intravenous administration Methods 0.000 description 40
• 239000003795 chemical substances by application Substances 0.000 description 39
• 239000001257 hydrogen Substances 0.000 description 39
• 238000012360 testing method Methods 0.000 description 39
• 210000002540 macrophage Anatomy 0.000 description 37
• 241000282414 Homo sapiens Species 0.000 description 35
• 210000004027 cell Anatomy 0.000 description 35
• 238000009472 formulation Methods 0.000 description 35
• 239000000679 carrageenan Substances 0.000 description 33
• 229920001525 carrageenan Polymers 0.000 description 33
• 229940113118 carrageenan Drugs 0.000 description 33
• 241000699670 Mus sp. Species 0.000 description 32
• 229910052799 carbon Inorganic materials 0.000 description 31
• 235000010418 carrageenan Nutrition 0.000 description 31
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 31
• 210000002683 foot Anatomy 0.000 description 30
• 206010065040 AIDS dementia complex Diseases 0.000 description 29
• 208000004454 Hyperalgesia Diseases 0.000 description 28
• 201000001119 neuropathy Diseases 0.000 description 28
• 230000007823 neuropathy Effects 0.000 description 28
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 28
• 206010012289 Dementia Diseases 0.000 description 27
• 241000713311 Simian immunodeficiency virus Species 0.000 description 27
• 208000012902 Nervous system disease Diseases 0.000 description 26
• 125000000623 heterocyclic group Chemical group 0.000 description 26
• 208000033808 peripheral neuropathy Diseases 0.000 description 26
• 229940124597 therapeutic agent Drugs 0.000 description 26
• 239000000126 substance Substances 0.000 description 25
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 23
• 208000025966 Neurological disease Diseases 0.000 description 23
• 241000700605 Viruses Species 0.000 description 23
• 125000004432 carbon atom Chemical group C* 0.000 description 23
• 210000003491 skin Anatomy 0.000 description 23
• 241000282412 Homo Species 0.000 description 22
• 206010061218 Inflammation Diseases 0.000 description 22
• 125000001931 aliphatic group Chemical group 0.000 description 22
• 238000001727 in vivo Methods 0.000 description 22
• 230000004054 inflammatory process Effects 0.000 description 22
• 230000002354 daily effect Effects 0.000 description 21
• 208000004296 neuralgia Diseases 0.000 description 21
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 20
• 238000004458 analytical method Methods 0.000 description 20
• 125000002950 monocyclic group Chemical group 0.000 description 20
• 208000021722 neuropathic pain Diseases 0.000 description 20
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 19
• 241000700159 Rattus Species 0.000 description 19
• 238000002347 injection Methods 0.000 description 19
• 239000007924 injection Substances 0.000 description 19
• 201000006417 multiple sclerosis Diseases 0.000 description 19
• 239000000546 pharmaceutical excipient Substances 0.000 description 19
• 125000003342 alkenyl group Chemical group 0.000 description 18
• 210000004369 blood Anatomy 0.000 description 18
• 239000008280 blood Substances 0.000 description 18
• 208000030507 AIDS Diseases 0.000 description 17
• 201000004681 Psoriasis Diseases 0.000 description 17
• 210000001744 T-lymphocyte Anatomy 0.000 description 17
• 125000003277 amino group Chemical group 0.000 description 17
• 238000005259 measurement Methods 0.000 description 17
• 229910052757 nitrogen Inorganic materials 0.000 description 17
• 239000000243 solution Substances 0.000 description 17
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 17
• 125000001424 substituent group Chemical group 0.000 description 17
• 230000003612 virological effect Effects 0.000 description 17
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
• 102100040557 Osteopontin Human genes 0.000 description 16
• 230000001684 chronic effect Effects 0.000 description 16
• 229940002612 prodrug Drugs 0.000 description 16
• 239000000651 prodrug Substances 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 238000001356 surgical procedure Methods 0.000 description 16
• 239000003826 tablet Substances 0.000 description 16
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 15
• 206010028980 Neoplasm Diseases 0.000 description 15
• 239000004480 active ingredient Substances 0.000 description 15
• 125000000753 cycloalkyl group Chemical group 0.000 description 15
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 14
• 229910005965 SO 2 Inorganic materials 0.000 description 14
• 239000002253 acid Substances 0.000 description 14
• 208000006673 asthma Diseases 0.000 description 14
• 210000003169 central nervous system Anatomy 0.000 description 14
• 239000007884 disintegrant Substances 0.000 description 14
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
• 229920006395 saturated elastomer Polymers 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 206010061598 Immunodeficiency Diseases 0.000 description 13
• 125000004429 atom Chemical group 0.000 description 13
• 239000002775 capsule Substances 0.000 description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
• 150000002431 hydrogen Chemical class 0.000 description 13
• 208000015181 infectious disease Diseases 0.000 description 13
• 206010039073 rheumatoid arthritis Diseases 0.000 description 13
• 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 12
• 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 206010014599 encephalitis Diseases 0.000 description 12
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 12
• 210000001616 monocyte Anatomy 0.000 description 12
• 125000004433 nitrogen atom Chemical group N* 0.000 description 12
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 12
• 208000024891 symptom Diseases 0.000 description 12
• 208000023275 Autoimmune disease Diseases 0.000 description 11
• 208000031886 HIV Infections Diseases 0.000 description 11
• 208000029462 Immunodeficiency disease Diseases 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 11
• 238000010171 animal model Methods 0.000 description 11
• 238000004364 calculation method Methods 0.000 description 11
• 230000006378 damage Effects 0.000 description 11
• 230000007813 immunodeficiency Effects 0.000 description 11
• 239000000314 lubricant Substances 0.000 description 11
• 239000000843 powder Substances 0.000 description 11
• 230000002062 proliferating effect Effects 0.000 description 11
• 229910052717 sulfur Inorganic materials 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 208000035154 Hyperesthesia Diseases 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 125000003545 alkoxy group Chemical group 0.000 description 10
• 206010053552 allodynia Diseases 0.000 description 10
• 229940024606 amino acid Drugs 0.000 description 10
• 239000003443 antiviral agent Substances 0.000 description 10
• 206010003246 arthritis Diseases 0.000 description 10
• 230000008901 benefit Effects 0.000 description 10
• 201000011510 cancer Diseases 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 229910052760 oxygen Inorganic materials 0.000 description 10
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
• 208000011580 syndromic disease Diseases 0.000 description 10
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 208000037357 HIV infectious disease Diseases 0.000 description 9
• 206010030113 Oedema Diseases 0.000 description 9
• 239000005700 Putrescine Substances 0.000 description 9
• 229960005305 adenosine Drugs 0.000 description 9
• 235000001014 amino acid Nutrition 0.000 description 9
• 150000001413 amino acids Chemical class 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 125000001072 heteroaryl group Chemical group 0.000 description 9
• 125000005842 heteroatom Chemical group 0.000 description 9
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 9
• 208000014674 injury Diseases 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
• 230000035755 proliferation Effects 0.000 description 9
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 239000012453 solvate Substances 0.000 description 9
• 229940063675 spermine Drugs 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 230000009885 systemic effect Effects 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• 206010061818 Disease progression Diseases 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 210000004712 air sac Anatomy 0.000 description 8
• 125000002723 alicyclic group Chemical group 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 230000003542 behavioural effect Effects 0.000 description 8
• 239000011230 binding agent Substances 0.000 description 8
• VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 8
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
• 208000010247 contact dermatitis Diseases 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• RPSHOHKFHRFBAZ-UHFFFAOYSA-N n'-[4-(4-aminobutylamino)butyl]butane-1,4-diamine Chemical compound NCCCCNCCCCNCCCCN RPSHOHKFHRFBAZ-UHFFFAOYSA-N 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 8
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 201000004624 Dermatitis Diseases 0.000 description 7
• 241000282560 Macaca mulatta Species 0.000 description 7
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 125000000304 alkynyl group Chemical group 0.000 description 7
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 7
• 201000008937 atopic dermatitis Diseases 0.000 description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 230000005750 disease progression Effects 0.000 description 7
• 210000000416 exudates and transudate Anatomy 0.000 description 7
• 239000000945 filler Substances 0.000 description 7
• 238000001802 infusion Methods 0.000 description 7
• 208000028867 ischemia Diseases 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000002503 metabolic effect Effects 0.000 description 7
• 229920000609 methyl cellulose Polymers 0.000 description 7
• 239000001923 methylcellulose Substances 0.000 description 7
• 235000010981 methylcellulose Nutrition 0.000 description 7
• 239000008108 microcrystalline cellulose Substances 0.000 description 7
• 229940016286 microcrystalline cellulose Drugs 0.000 description 7
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 230000001185 psoriatic effect Effects 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 238000006722 reduction reaction Methods 0.000 description 7
• 239000004094 surface-active agent Substances 0.000 description 7
• 230000032258 transport Effects 0.000 description 7
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 6
• ZAXCZCOUDLENMH-UHFFFAOYSA-N 3,3,3-tetramine Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 6
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
• 206010012442 Dermatitis contact Diseases 0.000 description 6
• 241000713800 Feline immunodeficiency virus Species 0.000 description 6
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
• 241001529936 Murinae Species 0.000 description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 230000000840 anti-viral effect Effects 0.000 description 6
• 208000010668 atopic eczema Diseases 0.000 description 6
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 239000000460 chlorine Substances 0.000 description 6
• 125000004093 cyano group Chemical group *C#N 0.000 description 6
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
• 229960003957 dexamethasone Drugs 0.000 description 6
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
• 230000002496 gastric effect Effects 0.000 description 6
• 229910052736 halogen Inorganic materials 0.000 description 6
• 150000002367 halogens Chemical class 0.000 description 6
• 150000004677 hydrates Chemical class 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• 229910052744 lithium Inorganic materials 0.000 description 6
• 229960001078 lithium Drugs 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 6
• 230000004770 neurodegeneration Effects 0.000 description 6
• 238000003305 oral gavage Methods 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 6
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 6
• 229940069328 povidone Drugs 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 229940063673 spermidine Drugs 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 229940032147 starch Drugs 0.000 description 6
• 235000019698 starch Nutrition 0.000 description 6
• UODZHRGDSPLRMD-UHFFFAOYSA-N sym-homospermidine Chemical compound NCCCCNCCCCN UODZHRGDSPLRMD-UHFFFAOYSA-N 0.000 description 6
• 230000009385 viral infection Effects 0.000 description 6
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 5
• 208000024827 Alzheimer disease Diseases 0.000 description 5
• 208000014644 Brain disease Diseases 0.000 description 5
• 208000011231 Crohn disease Diseases 0.000 description 5
• 206010012438 Dermatitis atopic Diseases 0.000 description 5
• 208000032274 Encephalopathy Diseases 0.000 description 5
• 208000009386 Experimental Arthritis Diseases 0.000 description 5
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
• 102000013691 Interleukin-17 Human genes 0.000 description 5
• 108050003558 Interleukin-17 Proteins 0.000 description 5
• 102000004889 Interleukin-6 Human genes 0.000 description 5
• 108090001005 Interleukin-6 Proteins 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 5
• 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 5
• 125000003368 amide group Chemical group 0.000 description 5
• 230000002917 arthritic effect Effects 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 239000004067 bulking agent Substances 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 125000004181 carboxyalkyl group Chemical group 0.000 description 5
• 229960000913 crospovidone Drugs 0.000 description 5
• 125000004122 cyclic group Chemical group 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 239000011737 fluorine Substances 0.000 description 5
• 229910052731 fluorine Inorganic materials 0.000 description 5
• 238000012948 formulation analysis Methods 0.000 description 5
• 125000004404 heteroalkyl group Chemical group 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 229940100601 interleukin-6 Drugs 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• 239000008101 lactose Substances 0.000 description 5
• 229960001375 lactose Drugs 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 230000007171 neuropathology Effects 0.000 description 5
• 150000007523 nucleic acids Chemical group 0.000 description 5
• 229920001983 poloxamer Polymers 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 238000005070 sampling Methods 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 210000001032 spinal nerve Anatomy 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 238000005303 weighing Methods 0.000 description 5
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 108010078791 Carrier Proteins Proteins 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
• 102000003849 Cytochrome P450 Human genes 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• 102000000589 Interleukin-1 Human genes 0.000 description 4
• 108010002352 Interleukin-1 Proteins 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 125000002947 alkylene group Chemical group 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 229940124522 antiretrovirals Drugs 0.000 description 4
• 239000003903 antiretrovirus agent Substances 0.000 description 4
• 125000003710 aryl alkyl group Chemical group 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
• 239000001768 carboxy methyl cellulose Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 206010009887 colitis Diseases 0.000 description 4
• 239000000562 conjugate Substances 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 4
• 230000006806 disease prevention Effects 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 210000001508 eye Anatomy 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 238000003304 gavage Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 210000000548 hind-foot Anatomy 0.000 description 4
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 230000008595 infiltration Effects 0.000 description 4
• 238000001764 infiltration Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 210000002414 leg Anatomy 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 230000007774 longterm Effects 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 230000002981 neuropathic effect Effects 0.000 description 4
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
• 230000003040 nociceptive effect Effects 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 3
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
• 101150051438 CYP gene Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 241000700198 Cavia Species 0.000 description 3
• 241000700199 Cavia porcellus Species 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 102000001326 Chemokine CCL4 Human genes 0.000 description 3
• 108010055165 Chemokine CCL4 Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 241000723346 Cinnamomum camphora Species 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 229920002785 Croscarmellose sodium Polymers 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010065390 Inflammatory pain Diseases 0.000 description 3
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
• 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 208000019695 Migraine disease Diseases 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 108010058846 Ovalbumin Proteins 0.000 description 3
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 3
• 108010089430 Phosphoproteins Proteins 0.000 description 3
• 102000007982 Phosphoproteins Human genes 0.000 description 3
• 206010035664 Pneumonia Diseases 0.000 description 3
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
• 208000004550 Postoperative Pain Diseases 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 108020000999 Viral RNA Proteins 0.000 description 3
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 3
• 229960000643 adenine Drugs 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 125000005275 alkylenearyl group Chemical group 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
• OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 229960000846 camphor Drugs 0.000 description 3
• 229930008380 camphor Natural products 0.000 description 3
• 125000001589 carboacyl group Chemical group 0.000 description 3
• 229910002092 carbon dioxide Inorganic materials 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 229940111134 coxibs Drugs 0.000 description 3
• 229960001681 croscarmellose sodium Drugs 0.000 description 3
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 201000001981 dermatomyositis Diseases 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000001647 drug administration Methods 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000002615 epidermis Anatomy 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 229940050410 gluconate Drugs 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 210000004209 hair Anatomy 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 230000009931 harmful effect Effects 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 230000000917 hyperalgesic effect Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000011081 inoculation Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 229960002725 isoflurane Drugs 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 206010027599 migraine Diseases 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
• 229940127240 opiate Drugs 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 210000000963 osteoblast Anatomy 0.000 description 3
• 229940092253 ovalbumin Drugs 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000008058 pain sensation Effects 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 229960005141 piperazine Drugs 0.000 description 3
• 229960000502 poloxamer Drugs 0.000 description 3
• 238000003752 polymerase chain reaction Methods 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 3
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 229960004793 sucrose Drugs 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 229930192474 thiophene Natural products 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 241001529453 unidentified herpesvirus Species 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 230000029812 viral genome replication Effects 0.000 description 3
• CYPGNVSXMAUSJY-CXUHLZMHSA-N (1e)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide Chemical compound C1=CC=C(C(N)=N)C2=C1C(=N/N=C(N)N)/CC2 CYPGNVSXMAUSJY-CXUHLZMHSA-N 0.000 description 2
• VRAHREWXGGWUKL-IVZWLZJFSA-N (2r,3s,5r)-2-[[2-aminooxyethyl(methyl)amino]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CON(CCON)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VRAHREWXGGWUKL-IVZWLZJFSA-N 0.000 description 2
• XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 2
• IYEWZPHRHXRMCW-BWZSZYTASA-N (2s,3s,4r,5r)-2-[[1-amino-8-(3-aminopropylamino)octan-3-yl]sulfanylmethyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC(CCN)CCCCCNCCCN)O[C@H]1N1C2=NC=NC(N)=C2N=C1 IYEWZPHRHXRMCW-BWZSZYTASA-N 0.000 description 2
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• XNCRUNXWPDJHGV-BQYQJAHWSA-N (e)-2-methyl-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(/C)=C/C1=CC=CC=C1 XNCRUNXWPDJHGV-BQYQJAHWSA-N 0.000 description 2
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 2
• JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 2
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 2
• JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 2
• UCGIIOJWRLQBRP-UHFFFAOYSA-N 5-methyl-3-phenyl-1,2-oxazole Chemical compound O1C(C)=CC(C=2C=CC=CC=2)=N1 UCGIIOJWRLQBRP-UHFFFAOYSA-N 0.000 description 2
• UHVNEMXXIPSZIQ-UHFFFAOYSA-N 7-chloro-2-(4-chlorophenyl)-6-methylquinoline Chemical compound N1=C2C=C(Cl)C(C)=CC2=CC=C1C1=CC=C(Cl)C=C1 UHVNEMXXIPSZIQ-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 102100036664 Adenosine deaminase Human genes 0.000 description 2
• 108010064733 Angiotensins Proteins 0.000 description 2
• 102000015427 Angiotensins Human genes 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 2
• 108010019625 Atazanavir Sulfate Proteins 0.000 description 2
• 206010003805 Autism Diseases 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000008035 Back Pain Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006458 Bronchitis chronic Diseases 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
• QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 108010055166 Chemokine CCL5 Proteins 0.000 description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 244000298479 Cichorium intybus Species 0.000 description 2
• 235000007542 Cichorium intybus Nutrition 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 206010011906 Death Diseases 0.000 description 2
• 206010012335 Dependence Diseases 0.000 description 2
• 206010012434 Dermatitis allergic Diseases 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 229920001353 Dextrin Polymers 0.000 description 2
• 239000004375 Dextrin Substances 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
• 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
• XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
• XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
• 108010032976 Enfuvirtide Proteins 0.000 description 2
• 108010008165 Etanercept Proteins 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 208000013016 Hypoglycemia Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 101710091439 Major capsid protein 1 Proteins 0.000 description 2
• 229920002774 Maltodextrin Polymers 0.000 description 2
• 239000005913 Maltodextrin Substances 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
• JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
• 206010029350 Neurotoxicity Diseases 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010030124 Oedema peripheral Diseases 0.000 description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
• 102100021079 Ornithine decarboxylase Human genes 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 208000004983 Phantom Limb Diseases 0.000 description 2
• 206010056238 Phantom pain Diseases 0.000 description 2
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 206010036618 Premenstrual syndrome Diseases 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 102000007365 Sialoglycoproteins Human genes 0.000 description 2
• 108010032838 Sialoglycoproteins Proteins 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 2
• XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 206010044221 Toxic encephalopathy Diseases 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 101710090322 Truncated surface protein Proteins 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 229960004748 abacavir Drugs 0.000 description 2
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
• 150000001242 acetic acid derivatives Chemical class 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 125000003282 alkyl amino group Chemical group 0.000 description 2
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
• 208000002029 allergic contact dermatitis Diseases 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• QZBYOYPROVGOGE-UHFFFAOYSA-N aminopropylcadaverine Chemical compound NCCCCCNCCCN QZBYOYPROVGOGE-UHFFFAOYSA-N 0.000 description 2
• 229960001830 amprenavir Drugs 0.000 description 2
• YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 229960003277 atazanavir Drugs 0.000 description 2
• AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 2
• GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 2
• 125000004069 aziridinyl group Chemical group 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
• 229940077388 benzenesulfonate Drugs 0.000 description 2
• 229940049706 benzodiazepine Drugs 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
• 108091006374 cAMP receptor proteins Proteins 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 230000009787 cardiac fibrosis Effects 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 208000007451 chronic bronchitis Diseases 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
• 239000008139 complexing agent Substances 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 230000008260 defense mechanism Effects 0.000 description 2
• 229960005319 delavirdine Drugs 0.000 description 2
• 235000019425 dextrin Nutrition 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 201000009101 diabetic angiopathy Diseases 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 229960002986 dinoprostone Drugs 0.000 description 2
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 229960003804 efavirenz Drugs 0.000 description 2
• XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
• 229960002062 enfuvirtide Drugs 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 230000002327 eosinophilic effect Effects 0.000 description 2
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 238000005187 foaming Methods 0.000 description 2
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 229960003142 fosamprenavir Drugs 0.000 description 2
• MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 229960001743 golimumab Drugs 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229920001519 homopolymer Polymers 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
• 230000002218 hypoglycaemic effect Effects 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 229940099472 immunoglobulin a Drugs 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 229960001936 indinavir Drugs 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 229960003350 isoniazid Drugs 0.000 description 2
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 230000013016 learning Effects 0.000 description 2
• 229960004525 lopinavir Drugs 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 235000018977 lysine Nutrition 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 229940035034 maltodextrin Drugs 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000015654 memory Effects 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
• 229960000282 metronidazole Drugs 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 201000005518 mononeuropathy Diseases 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• QXOCYGPVDXDFLC-UHFFFAOYSA-N n-ethyl-n'-[4-[4-(ethylamino)butylamino]butyl]butane-1,4-diamine Chemical compound CCNCCCCNCCCCNCCCCNCC QXOCYGPVDXDFLC-UHFFFAOYSA-N 0.000 description 2
• 210000003739 neck Anatomy 0.000 description 2
• 229960000884 nelfinavir Drugs 0.000 description 2
• QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 230000007135 neurotoxicity Effects 0.000 description 2
• 231100000228 neurotoxicity Toxicity 0.000 description 2
• 229960000689 nevirapine Drugs 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 230000037311 normal skin Effects 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 229960003104 ornithine Drugs 0.000 description 2
• 239000003002 pH adjusting agent Substances 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 description 2
• SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 2
• 229950000688 phenothiazine Drugs 0.000 description 2
• ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• 231100000572 poisoning Toxicity 0.000 description 2
• 230000000607 poisoning effect Effects 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 229920003124 powdered cellulose Polymers 0.000 description 2
• 235000019814 powdered cellulose Nutrition 0.000 description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
• 230000001566 pro-viral effect Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000006268 reductive amination reaction Methods 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 229960000311 ritonavir Drugs 0.000 description 2
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 229960001852 saquinavir Drugs 0.000 description 2
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 229940080313 sodium starch Drugs 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 208000003265 stomatitis Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
• ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 2
• DODDBCGMRAFLEB-UHFFFAOYSA-N thermospermine Chemical compound NCCCCNCCCNCCCN DODDBCGMRAFLEB-UHFFFAOYSA-N 0.000 description 2
• 229960000838 tipranavir Drugs 0.000 description 2
• SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 208000004371 toothache Diseases 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• KVSKGMLNBAPGKH-UHFFFAOYSA-N tribromosalicylanilide Chemical compound OC1=C(Br)C=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 KVSKGMLNBAPGKH-UHFFFAOYSA-N 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000036269 ulceration Effects 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
• 229960002555 zidovudine Drugs 0.000 description 2
• NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• MNYQIJBXEIRCJO-YFKPBYRVSA-N (2S)-5-amino-2-[fluoro(methyl)amino]pentanoic acid Chemical compound CN(F)[C@H](C(O)=O)CCCN MNYQIJBXEIRCJO-YFKPBYRVSA-N 0.000 description 1
• ZSQSLFXPAOWQAQ-RXMQYKEDSA-N (2r)-2,5-diamino-2-hydrazinylpentanoic acid Chemical compound NCCC[C@@](N)(NN)C(O)=O ZSQSLFXPAOWQAQ-RXMQYKEDSA-N 0.000 description 1
• VLRCFULRQZKFRM-KQYNXXCUSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-sulfanyloxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1S VLRCFULRQZKFRM-KQYNXXCUSA-N 0.000 description 1
• ZLGKOOYLCJDFHS-WOUKDFQISA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-ethylsulfanyl-2-(hydroxymethyl)oxolan-3-ol Chemical compound CCS[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZLGKOOYLCJDFHS-WOUKDFQISA-N 0.000 description 1
• HLJHWWUZHBUUAC-KQYNXXCUSA-N (2r,3r,4s,5s)-2-(6-aminopurin-9-yl)-5-(sulfanylmethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CS)[C@@H](O)[C@H]1O HLJHWWUZHBUUAC-KQYNXXCUSA-N 0.000 description 1
• GVSGUDGNTHCZHI-KQYNXXCUSA-N (2r,3s,4r,5r)-2-(aminomethyl)-5-(6-aminopurin-9-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN)O[C@H]1N1C2=NC=NC(N)=C2N=C1 GVSGUDGNTHCZHI-KQYNXXCUSA-N 0.000 description 1
• MSHFOWYMHIZSJV-QYVSTXNMSA-N (2r,3s,4r,5r)-2-[(3-aminopropylamino)methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CNCCCN)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MSHFOWYMHIZSJV-QYVSTXNMSA-N 0.000 description 1
• YWJCZGDVJQLZET-GGHFOJMISA-N (2r,3s,4r,5r)-2-[[[(z)-4-aminobut-2-enyl]-methylamino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN(C\C=C/CN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 YWJCZGDVJQLZET-GGHFOJMISA-N 0.000 description 1
• LNDPCYHWPSQBCA-LURJTMIESA-N (2s)-2,5-diamino-2-methylpentanoic acid Chemical compound OC(=O)[C@](N)(C)CCCN LNDPCYHWPSQBCA-LURJTMIESA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• JLUPGSPHOGFEOB-WQLSENKSSA-N (2z)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O\1C(C)(C)OC(=O)C/1=C/C(=O)N(OC)CC1=CC=C(F)C=C1 JLUPGSPHOGFEOB-WQLSENKSSA-N 0.000 description 1
• KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 description 1
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• POPHMOPNVVKGRW-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydronaphthalene Chemical compound C1CCC2CCCCC2=C1 POPHMOPNVVKGRW-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
• IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
• DBPMWRYLTBNCCE-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CN=C(OC)C=2NC=C1C(=O)C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 DBPMWRYLTBNCCE-UHFFFAOYSA-N 0.000 description 1
• LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 description 1
• MPBKAOHKPAKJDA-VCHYOVAHSA-N 2-(3-aminopropyl)-1-[(e)-(2,2-difluoro-1-phenylethylidene)amino]guanidine Chemical compound NCCCN=C(N)N\N=C(\C(F)F)C1=CC=CC=C1 MPBKAOHKPAKJDA-VCHYOVAHSA-N 0.000 description 1
• TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
• DDNVYHHARMNUBE-HMMKTVFPSA-N 2-[(e)-[(1e)-1-(diaminomethylidenehydrazinylidene)butan-2-ylidene]amino]guanidine Chemical compound NC(N)=N\N=C(/CC)\C=N\N=C(N)N DDNVYHHARMNUBE-HMMKTVFPSA-N 0.000 description 1
• QCPPROTWPVZXKL-HMMKTVFPSA-N 2-[(e)-[(3e)-3-(diaminomethylidenehydrazinylidene)butan-2-ylidene]amino]guanidine Chemical compound NC(N)=N\N=C(/C)\C(\C)=N\N=C(N)N QCPPROTWPVZXKL-HMMKTVFPSA-N 0.000 description 1
• HXWLLFLQUZOBFF-FUJGBLOQSA-N 2-[(z)-[(4e)-4-(diaminomethylidenehydrazinylidene)hexan-3-ylidene]amino]guanidine Chemical compound NC(N)=N/N=C(/CC)\C(\CC)=N\N=C(N)N HXWLLFLQUZOBFF-FUJGBLOQSA-N 0.000 description 1
• FMUAWDFGCWFINE-UHFFFAOYSA-N 2-[3-aminopropyl-[4-(3-aminopropylamino)butyl]amino]guanidine Chemical compound NCCCNCCCCN(NC(N)=N)CCCN FMUAWDFGCWFINE-UHFFFAOYSA-N 0.000 description 1
• LDROJWRKRBGRGX-UHFFFAOYSA-N 2-[4-(methylamino)butyl]guanidine Chemical compound CNCCCCN=C(N)N LDROJWRKRBGRGX-UHFFFAOYSA-N 0.000 description 1
• ICNJXCLTISTRAH-UHFFFAOYSA-N 2-[4-[4-[4-[4-(ethylamino)butylamino]butylamino]butylamino]butylamino]ethanol Chemical compound CCNCCCCNCCCCNCCCCNCCCCNCCO ICNJXCLTISTRAH-UHFFFAOYSA-N 0.000 description 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• SRKQUQMCVHDJDD-WCEDTRLTSA-N 2-cyclohexyl-1-[(e)-[(1e)-1-[(n'-cyclohexylcarbamimidoyl)hydrazinylidene]propan-2-ylidene]amino]guanidine Chemical compound C1CCCCC1N=C(N)N\N=C(/C)\C=N\NC(N)=NC1CCCCC1 SRKQUQMCVHDJDD-WCEDTRLTSA-N 0.000 description 1
• GGQJPAQXCYUEKB-UHFFFAOYSA-N 2-methylbutane-1,4-diamine Chemical compound NCC(C)CCN GGQJPAQXCYUEKB-UHFFFAOYSA-N 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 description 1
• NMSWNFUNBWTSMA-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-methyl-1,2-oxazole Chemical compound O1C(C)=CC(C=2C(=CC=CC=2)Cl)=N1 NMSWNFUNBWTSMA-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
• ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
• WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
• 125000002124 5'-adenosyl group Chemical group N1=CN=C2N(C=NC2=C1N)[C@H]1[C@H](O)[C@H](O)[C@H](O1)C* 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• RMAOLICYOBWFLA-VCZNENMGSA-N 5'-{[2-(aminooxy)ethyl](methyl)sulfonio}-5'-deoxyadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CCON)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RMAOLICYOBWFLA-VCZNENMGSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
• 150000000640 6-keto-prostaglandin F1α derivatives Chemical class 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
• XEYBRNLFEZDVAW-DODZYUBVSA-N 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CC=CCCCC(O)=O XEYBRNLFEZDVAW-DODZYUBVSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 101800000263 Acidic protein Proteins 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• 208000004804 Adenomatous Polyps Diseases 0.000 description 1
• QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
• 208000000884 Airway Obstruction Diseases 0.000 description 1
• 206010001605 Alcohol poisoning Diseases 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 206010003557 Asthma exercise induced Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006298 Breast pain Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
• YZSXFULDCZENBC-UHFFFAOYSA-N CC(CC)NCCCCN.NOCCCN Chemical compound CC(CC)NCCCCN.NOCCCN YZSXFULDCZENBC-UHFFFAOYSA-N 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• NIDRYBLTWYFCFV-IUUKEHGRSA-N Calanolide A Natural products C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-IUUKEHGRSA-N 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 206010007710 Cartilage injury Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010068051 Chimerism Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000019399 Colonic disease Diseases 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 206010055665 Corneal neovascularisation Diseases 0.000 description 1
• 206010011409 Cross infection Diseases 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• 208000026292 Cystic Kidney disease Diseases 0.000 description 1
• 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
• 206010012692 Diabetic uveitis Diseases 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
• 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 206010061825 Duodenal neoplasm Diseases 0.000 description 1
• 206010013935 Dysmenorrhoea Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 208000003241 Fat Embolism Diseases 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 208000036119 Frailty Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 206010051920 Glomerulonephropathy Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010058490 Hyperoxia Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 108091058560 IL8 Proteins 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 208000002971 Immunoblastic Lymphadenopathy Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• FQPGMQABJNQLLF-VKHMYHEASA-N L-canaline Chemical compound NOCC[C@H](N)C(O)=O FQPGMQABJNQLLF-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 101710091437 Major capsid protein 2 Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000006662 Mastodynia Diseases 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 208000034388 Mountain sickness acute Diseases 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100191385 Mus musculus Prkdc gene Proteins 0.000 description 1
• 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• ZZKUVWAIJULWKG-UHFFFAOYSA-N N'-[2-(3-aminopropylamino)ethyl]propane-1,3-diamine N'-(3-aminopropyl)propane-1,3-diamine Chemical compound NCCCNCCCN.NCCCNCCNCCCN ZZKUVWAIJULWKG-UHFFFAOYSA-N 0.000 description 1
• PGMIWVSHZMWSSI-UHFFFAOYSA-N N(1),N(12)-diethylspermine Chemical compound CCNCCCNCCCCNCCCNCC PGMIWVSHZMWSSI-UHFFFAOYSA-N 0.000 description 1
• MQTAVJHICJWXBR-UHFFFAOYSA-N N(1)-acetylspermidine Chemical compound CC(=O)NCCCNCCCCN MQTAVJHICJWXBR-UHFFFAOYSA-N 0.000 description 1
• GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 description 1
• CAARYRKDWMNHCB-UHFFFAOYSA-N N(4)-aminopropylspermidine Chemical compound NCCCCN(CCCN)CCCN CAARYRKDWMNHCB-UHFFFAOYSA-N 0.000 description 1
• FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 description 1
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 208000007117 Oral Ulcer Diseases 0.000 description 1
• 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000000114 Pain Threshold Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 241001111421 Pannus Species 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 108010001441 Phosphopeptides Proteins 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 206010070308 Refractory cancer Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010038423 Renal cyst Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010040030 Sensory loss Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• 206010040880 Skin irritation Diseases 0.000 description 1
• 206010054184 Small intestine carcinoma Diseases 0.000 description 1
• 108010051753 Spermidine Synthase Proteins 0.000 description 1
• 102100030413 Spermidine synthase Human genes 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000001163 Tangier disease Diseases 0.000 description 1
• WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 206010043647 Thrombotic Stroke Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
• 208000003056 Vitamin B6 deficiency Diseases 0.000 description 1
• 206010047631 Vitamin E deficiency Diseases 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000036866 Vitreoretinopathy Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010072731 White matter lesion Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 229920002494 Zein Polymers 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 238000005299 abrasion Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000007950 acidosis Effects 0.000 description 1
• 208000026545 acidosis disease Diseases 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 229940119059 actemra Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 208000018315 acute mountain sickness Diseases 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960001997 adefovir Drugs 0.000 description 1
• WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000005273 aeration Methods 0.000 description 1
• QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
• 230000036428 airway hyperreactivity Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 229950004424 alovudine Drugs 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 229960001097 amifostine Drugs 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
• 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003070 anti-hyperalgesia Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 230000009925 apoptotic mechanism Effects 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000001483 arginine derivatives Chemical class 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 125000001769 aryl amino group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 208000037875 astrocytosis Diseases 0.000 description 1
• 230000007341 astrogliosis Effects 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000006736 behavioral deficit Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
• LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
• 238000011953 bioanalysis Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 230000010478 bone regeneration Effects 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 1
• 229950009079 brecanavir Drugs 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 229940078456 calcium stearate Drugs 0.000 description 1
• 235000019577 caloric intake Nutrition 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001717 carbocyclic compounds Chemical class 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 238000007675 cardiac surgery Methods 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 230000001767 chemoprotection Effects 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229940090100 cimzia Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 230000008951 colonic inflammation Effects 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 230000002508 compound effect Effects 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 210000005257 cortical tissue Anatomy 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940117173 croton oil Drugs 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000037416 cystogenesis Effects 0.000 description 1
• 229960000860 dapsone Drugs 0.000 description 1
• 229960005107 darunavir Drugs 0.000 description 1
• CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
• 210000003785 decidua Anatomy 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000000645 desinfectant Substances 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229940096516 dextrates Drugs 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical group CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
• 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 229960002563 disulfiram Drugs 0.000 description 1
• 229960002311 dithranol Drugs 0.000 description 1
• 229960000878 docusate sodium Drugs 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 201000000312 duodenum cancer Diseases 0.000 description 1
• 210000003027 ear inner Anatomy 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 125000006575 electron-withdrawing group Chemical group 0.000 description 1
• 229950006528 elvucitabine Drugs 0.000 description 1
• 229960000366 emtricitabine Drugs 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
• 230000003631 expected effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 231100000040 eye damage Toxicity 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 229960005102 foscarnet Drugs 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 229960005219 gentisic acid Drugs 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
• 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 229940124784 gp41 inhibitor Drugs 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000009499 grossing Methods 0.000 description 1
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 238000011554 guinea pig model Methods 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 125000004995 haloalkylthio group Chemical group 0.000 description 1
• 125000000232 haloalkynyl group Chemical group 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000003084 hiv integrase inhibitor Substances 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 239000004093 hydrolase inhibitor Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 230000000222 hyperoxic effect Effects 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229940124524 integrase inhibitor Drugs 0.000 description 1
• 239000002850 integrase inhibitor Substances 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 208000030776 invasive breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229960001021 lactose monohydrate Drugs 0.000 description 1
• 229960001627 lamivudine Drugs 0.000 description 1
• JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
• 229940127021 low-dose drug Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 229960003803 meclofenamic acid Drugs 0.000 description 1
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
• 229960002329 methacholine Drugs 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960004452 methionine Drugs 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 244000309715 mini pig Species 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
• 229950010514 misonidazole Drugs 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 229950008798 mozenavir Drugs 0.000 description 1
• 238000007837 multiplex assay Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• PTZGXPPKZDPKNJ-UHFFFAOYSA-N n',n'-bis(3-aminopropyl)pentane-1,5-diamine Chemical compound NCCCCCN(CCCN)CCCN PTZGXPPKZDPKNJ-UHFFFAOYSA-N 0.000 description 1
• KLZJZMUWHKIHHB-UHFFFAOYSA-N n',n'-bis[3-(ethylamino)propyl]heptane-1,7-diamine Chemical compound CCNCCCN(CCCNCC)CCCCCCCN KLZJZMUWHKIHHB-UHFFFAOYSA-N 0.000 description 1
• BKISDFRMYYNEKU-UHFFFAOYSA-N n'-[4-(3-aminopropylamino)butyl]butane-1,4-diamine Chemical compound NCCCCNCCCCNCCCN BKISDFRMYYNEKU-UHFFFAOYSA-N 0.000 description 1
• ONCPEIKLFULSSA-UHFFFAOYSA-N n'-ethylbutane-1,4-diamine Chemical compound CCNCCCCN ONCPEIKLFULSSA-UHFFFAOYSA-N 0.000 description 1
• VJACJUQFGYLDMG-UHFFFAOYSA-N n'-hexan-2-ylbutane-1,4-diamine Chemical compound CCCCC(C)NCCCCN VJACJUQFGYLDMG-UHFFFAOYSA-N 0.000 description 1
• FBJWOCSWSGEYRJ-UHFFFAOYSA-N n'-propan-2-ylbutane-1,4-diamine Chemical compound CC(C)NCCCCN FBJWOCSWSGEYRJ-UHFFFAOYSA-N 0.000 description 1
• BNINYDLMPMXBIA-UHFFFAOYSA-N n,n'-bis(3-aminopropyl)pentane-1,5-diamine Chemical compound NCCCNCCCCCNCCCN BNINYDLMPMXBIA-UHFFFAOYSA-N 0.000 description 1
• WIOJAQYPAPCEMC-UHFFFAOYSA-N n,n'-bis[3-(ethylamino)propyl]heptane-1,7-diamine Chemical compound CCNCCCNCCCCCCCNCCCNCC WIOJAQYPAPCEMC-UHFFFAOYSA-N 0.000 description 1
• PCRVCIMIOTWSNM-UHFFFAOYSA-N n,n'-dipropylpropane-1,3-diamine Chemical compound CCCNCCCNCCC PCRVCIMIOTWSNM-UHFFFAOYSA-N 0.000 description 1
• UQEIFYRRSNJVDO-UHFFFAOYSA-N n,n-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
• OPQAPLJOJPASNY-UHFFFAOYSA-N n-(2-methylsulfanylethyl)hydroxylamine Chemical compound CSCCNO OPQAPLJOJPASNY-UHFFFAOYSA-N 0.000 description 1
• RXOMMWRZPQYBPT-UHFFFAOYSA-N n-(3-aminopropyl)-n'-[3-(3-aminopropylamino)propyl]butane-1,4-diamine Chemical compound NCCCNCCCCNCCCNCCCN RXOMMWRZPQYBPT-UHFFFAOYSA-N 0.000 description 1
• GMPAHNFBSGCUHV-UHFFFAOYSA-N n-(3-aminopropyl)-n'-[3-(ethylamino)propyl]butane-1,4-diamine Chemical compound CCNCCCNCCCCNCCCN GMPAHNFBSGCUHV-UHFFFAOYSA-N 0.000 description 1
• NPPQUDMGFNXAFH-UHFFFAOYSA-N n-ethyl-n'-[4-[4-[4-(ethylamino)butylamino]butylamino]butyl]butane-1,4-diamine Chemical compound CCNCCCCNCCCCNCCCCNCCCCNCC NPPQUDMGFNXAFH-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000007230 neural mechanism Effects 0.000 description 1
• 230000008904 neural response Effects 0.000 description 1
• 230000001722 neurochemical effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 208000013315 neuromuscular junction disease Diseases 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 230000002276 neurotropic effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 150000002826 nitrites Chemical class 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
• 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
• 229950006344 nocodazole Drugs 0.000 description 1
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• VSZFWDPIWSPZON-UHFFFAOYSA-N o-(3-aminopropyl)hydroxylamine Chemical compound NCCCON VSZFWDPIWSPZON-UHFFFAOYSA-N 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 229950005751 ocrelizumab Drugs 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940126701 oral medication Drugs 0.000 description 1
• 229940035567 orencia Drugs 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002892 organic cations Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000008533 pain sensitivity Effects 0.000 description 1
• 230000037040 pain threshold Effects 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 229960004662 parecoxib Drugs 0.000 description 1
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000008289 pathophysiological mechanism Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 208000000689 peptic esophagitis Diseases 0.000 description 1
• 239000000863 peptide conjugate Substances 0.000 description 1
• 125000001151 peptidyl group Chemical group 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 235000008729 phenylalanine Nutrition 0.000 description 1
• SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
• 229940067157 phenylhydrazine Drugs 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
• USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 238000013310 pig model Methods 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 150000005599 propionic acid derivatives Chemical class 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 150000003244 quercetin derivatives Chemical class 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 210000003497 sciatic nerve Anatomy 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• 230000011218 segmentation Effects 0.000 description 1
• DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 125000005629 sialic acid group Chemical group 0.000 description 1
• 229940068638 simponi Drugs 0.000 description 1
• 230000037380 skin damage Effects 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 230000036556 skin irritation Effects 0.000 description 1
• 231100000475 skin irritation Toxicity 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000013076 target substance Substances 0.000 description 1
• WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 229960004556 tenofovir Drugs 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BDOBMVIEWHZYDL-UHFFFAOYSA-N tetrachlorosalicylanilide Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(=O)NC1=CC=CC=C1 BDOBMVIEWHZYDL-UHFFFAOYSA-N 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 230000003685 thermal hair damage Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000774 toxicodynamics Toxicity 0.000 description 1
• 231100000607 toxicokinetics Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229940078499 tricalcium phosphate Drugs 0.000 description 1
• 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
• 235000019731 tricalcium phosphate Nutrition 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
• 235000019158 vitamin B6 Nutrition 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 229940009065 wellbutrin Drugs 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• 239000005019 zein Substances 0.000 description 1
• 229940093612 zein Drugs 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• 229940018503 zyban Drugs 0.000 description 1